Surrozen (SRZN) Competitors

Surrozen logo
$28.46 -2.21 (-7.21%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$28.46 -0.01 (-0.02%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SRZN vs. BEAM, CLDX, LKFT, PVLA, and IMNM

Should you buy Surrozen stock or one of its competitors? Surrozen's main competitors and comparable companies include Beam Therapeutics (BEAM), Celldex Therapeutics (CLDX), Lakefront Biotherapeutics American Depositary Shares (LKFT), Palvella Therapeutics (PVLA), and Immunome (IMNM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Surrozen compare to Beam Therapeutics?

Surrozen (NASDAQ:SRZN) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Surrozen has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market.

Beam Therapeutics has higher revenue and earnings than Surrozen. Beam Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surrozen$3.48M155.88-$242.03M-$43.21N/A
Beam Therapeutics$146.64M14.72-$79.99M-$1.04N/A

In the previous week, Beam Therapeutics had 2 more articles in the media than Surrozen. MarketBeat recorded 4 mentions for Beam Therapeutics and 2 mentions for Surrozen. Beam Therapeutics' average media sentiment score of 0.31 beat Surrozen's score of 0.09 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Surrozen
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Beam Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Beam Therapeutics has a net margin of -73.04% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat Beam Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Surrozen-2,885.33% N/A -112.96%
Beam Therapeutics -73.04%-32.76%-25.80%

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 31.7% of Surrozen shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Surrozen currently has a consensus price target of $61.75, indicating a potential upside of 116.97%. Beam Therapeutics has a consensus price target of $47.64, indicating a potential upside of 128.35%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Surrozen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Surrozen
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Beam Therapeutics
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.75

Summary

Beam Therapeutics beats Surrozen on 13 of the 16 factors compared between the two stocks.

How does Surrozen compare to Celldex Therapeutics?

Surrozen (NASDAQ:SRZN) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Surrozen currently has a consensus price target of $61.75, suggesting a potential upside of 116.97%. Celldex Therapeutics has a consensus price target of $63.33, suggesting a potential upside of 131.40%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Celldex Therapeutics is more favorable than Surrozen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Surrozen
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77

In the previous week, Celldex Therapeutics had 6 more articles in the media than Surrozen. MarketBeat recorded 8 mentions for Celldex Therapeutics and 2 mentions for Surrozen. Surrozen's average media sentiment score of 0.09 beat Celldex Therapeutics' score of -0.46 indicating that Surrozen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Surrozen
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Celldex Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral

Celldex Therapeutics has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat Celldex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Surrozen-2,885.33% N/A -112.96%
Celldex Therapeutics N/A -52.66%-47.58%

Surrozen has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

Surrozen has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surrozen$3.48M155.88-$242.03M-$43.21N/A
Celldex Therapeutics$1.54M1,396.23-$258.76M-$4.30N/A

66.6% of Surrozen shares are held by institutional investors. 31.7% of Surrozen shares are held by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Celldex Therapeutics beats Surrozen on 9 of the 15 factors compared between the two stocks.

How does Surrozen compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Surrozen (NASDAQ:SRZN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Surrozen. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares$1.26B1.74$363.05M-$1.41N/A
Surrozen$3.48M155.88-$242.03M-$43.21N/A

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 15 more articles in the media than Surrozen. MarketBeat recorded 17 mentions for Lakefront Biotherapeutics American Depositary Shares and 2 mentions for Surrozen. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 1.00 beat Surrozen's score of 0.09 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares
7 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Surrozen
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%.

Company Net Margins Return on Equity Return on Assets
Lakefront Biotherapeutics American Depositary SharesN/A N/A N/A
Surrozen -2,885.33%N/A -112.96%

Lakefront Biotherapeutics American Depositary Shares currently has a consensus target price of $36.00, suggesting a potential upside of 8.21%. Surrozen has a consensus target price of $61.75, suggesting a potential upside of 116.97%. Given Surrozen's stronger consensus rating and higher probable upside, analysts clearly believe Surrozen is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lakefront Biotherapeutics American Depositary Shares
0 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.50
Surrozen
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Comparatively, 31.7% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Summary

Lakefront Biotherapeutics American Depositary Shares beats Surrozen on 8 of the 15 factors compared between the two stocks.

How does Surrozen compare to Palvella Therapeutics?

Surrozen (NASDAQ:SRZN) and Palvella Therapeutics (NASDAQ:PVLA) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Palvella Therapeutics has higher revenue and earnings than Surrozen. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surrozen$3.48M155.88-$242.03M-$43.21N/A
Palvella Therapeutics$42.81M48.78-$41.72M-$5.50N/A

Surrozen has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.21, indicating that its stock price is 121% less volatile than the broader market.

In the previous week, Palvella Therapeutics had 15 more articles in the media than Surrozen. MarketBeat recorded 17 mentions for Palvella Therapeutics and 2 mentions for Surrozen. Palvella Therapeutics' average media sentiment score of 0.39 beat Surrozen's score of 0.09 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Surrozen
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Palvella Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Surrozen presently has a consensus target price of $61.75, suggesting a potential upside of 116.97%. Palvella Therapeutics has a consensus target price of $214.86, suggesting a potential upside of 50.41%. Given Surrozen's higher possible upside, analysts plainly believe Surrozen is more favorable than Palvella Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Surrozen
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Palvella Therapeutics
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
1 Strong Buy rating(s)
2.94

Palvella Therapeutics has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat Palvella Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Surrozen-2,885.33% N/A -112.96%
Palvella Therapeutics N/A -44.44%-36.75%

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Palvella Therapeutics beats Surrozen on 10 of the 16 factors compared between the two stocks.

How does Surrozen compare to Immunome?

Immunome (NASDAQ:IMNM) and Surrozen (NASDAQ:SRZN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

In the previous week, Immunome had 1 more articles in the media than Surrozen. MarketBeat recorded 3 mentions for Immunome and 2 mentions for Surrozen. Surrozen's average media sentiment score of 0.09 beat Immunome's score of 0.01 indicating that Surrozen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immunome
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Surrozen
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Immunome has a beta of 2.68, meaning that its share price is 168% more volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

Immunome has higher revenue and earnings than Surrozen. Immunome is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immunome$6.94M266.59-$212.39M-$2.64N/A
Surrozen$3.48M155.88-$242.03M-$43.21N/A

Immunome has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat Immunome's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunomeN/A -51.33% -47.63%
Surrozen -2,885.33%N/A -112.96%

Immunome currently has a consensus target price of $33.85, indicating a potential upside of 115.99%. Surrozen has a consensus target price of $61.75, indicating a potential upside of 116.97%. Given Surrozen's higher possible upside, analysts clearly believe Surrozen is more favorable than Immunome.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunome
1 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.81
Surrozen
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

44.6% of Immunome shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 7.2% of Immunome shares are owned by company insiders. Comparatively, 31.7% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Immunome beats Surrozen on 10 of the 15 factors compared between the two stocks.

Get Surrozen News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRZN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRZN vs. The Competition

MetricSurrozenBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$542.51M$3.92B$7.44B$10.86B
Dividend YieldN/A3.79%2.51%4.68%
P/E Ratio-0.6623.0732.5628.68
Price / Sales51.5314.647.665.19
Price / CashN/A21.9220.2520.77
Price / Book-1.624.124.343.51
Net Income-$242.03M-$24.08M$3.51B$394.12M
7 Day Performance-9.97%-9.85%-8.07%-8.97%
1 Month Performance10.52%-12.77%-10.29%-11.61%
1 Year Performance115.61%-7.99%-4.70%-11.21%

Surrozen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SRZN
Surrozen
2.1959 of 5 stars
$28.46
-7.2%
$61.75
+117.0%
+115.6%$542.51M$10.53MN/A44
BEAM
Beam Therapeutics
2.3367 of 5 stars
$22.86
-4.9%
$47.64
+108.3%
-6.1%$2.36B$146.64MN/A540
CLDX
Celldex Therapeutics
1.5233 of 5 stars
$28.83
+1.1%
$64.08
+122.3%
+5.6%$2.26B$158KN/A198
LKFT
Lakefront Biotherapeutics American Depositary Shares
2.4765 of 5 stars
$33.98
+0.1%
$35.50
+4.5%
+8.5%$2.24B$1.26BN/A1,310
PVLA
Palvella Therapeutics
2.2152 of 5 stars
$152.48
-0.5%
$213.85
+40.2%
+51.8%$2.23B$42.81MN/A29

Related Companies and Tools


This page (NASDAQ:SRZN) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners